Novartis Didn't Expand Beyond Its Core. It Spent 27 Years Walking Back to It.

By the early twentieth century, the bottle of cough syrup, the bag of crop chemicals, the dyes, the early pharmaceuticals, and the chemicals that would eventually become blockbusters all traced back to the same cluster of Basel houses—Ciba, Geigy, and Sandoz—whose fates were already intertwined. By 2023 they couldn't. On October 4, 2023, the generics business that bore one of the company's two founding names walked out the door as an independent firm trading under its own ticker on the Swiss exchange.²⁴ Novartis, the company so often used as a case study in expanding beyond your core, had just finished doing the opposite. It had spent the better part of three decades giving the adjacencies back.

The official story is that Novartis is a diversification success - a 1996 merger that built a life-sciences powerhouse and then grew outward into vaccines, consumer health, eye care, generics. Almost every beat of that is backwards. The merger did assemble the breadth. But the strategy that defines the modern company isn't expansion into adjacencies. It's the patient, expensive work of selling them off one at a time.

The merger built a conglomerate; the years since dismantled it

Novartis was born in 1996 from the merger of Ciba-Geigy and Sandoz, two Swiss houses whose roots run back more than 250 years.¹ What they combined into was not a focused pharmaceutical company but a sprawling life-sciences group - drugs, generics, eye care, animal and crop chemistry, consumer brands. For a company later sold as a model of bold adjacency moves, the truth is that it started with too many cores and then chose which ones to keep. The interesting decisions all came later, and they all pointed the same way: out.

From 2015 onward, the moves form a single unmistakable pattern. Vaccines went to GSK in March 2015.⁹ The consumer-healthcare joint venture formed with GSK in 2015 was unwound when Novartis sold its 36.5% stake back to GSK for USD 13.0 billion, completed June 1, 2018.⁵ Alcon, the eye-care arm, was spun off as a standalone company on April 9, 2019.¹⁰ And in 2023, the Sandoz generics business - the one carrying a founding name - was spun off entirely.² Four exits, one direction. The company didn't reach for new ground. It retreated to old ground and fenced it.

Here is the thesis a smart friend could repeat at dinner: Novartis's famous adjacency story is really a contraction story. The portfolio diversification it built in the 1990s was steadily reversed, and the one expansion that actually created enormous value was never a business at all - it was a molecule.

Why a pure-play medicines core is worth more than the sum of the parts

The logic underneath the retreat is not sentimental and it is not random. An innovative-medicines business and a generics business look like cousins, but they are run on opposite physics. One competes on a patented breakthrough that earns extraordinary margins for a protected window; the other competes on manufacturing cost the moment the patent expires. Eye-care surgery and over-the-counter cough syrup are different again - different customers, different sales forces, different capital. Strapping them to the same balance sheet doesn't multiply advantage. It dilutes management attention and forces a single share price to average out businesses the market would rather value separately.

So the divestitures weren't admissions of failure. They were a recognition that the conglomerate discount is real. By the time Sandoz left, the continuing business reported FY2023 net sales of USD 44.6 billion, up from USD 41.4 billion the year before³ - a focused engine growing on its own terms, no longer carrying the lower-margin generics franchise on its books. The point of cutting away the adjacencies was to let the part that compounds compound, and to let a buyer who could run a generics business better - or a public market that could value it cleanly - take the part that didn't fit.

The adjacency that actually paid was a single molecule

If the portfolio diversification was the expansion everyone talks about, the expansion that mattered hid inside the lab. In the late 1990s a biochemist named Nicholas Lyndon, then working at Ciba-Geigy, invented a compound called imatinib; the clinical work that turned it against chronic myeloid leukemia was driven by Brian Druker.⁸ Sold as Gleevec, it won accelerated FDA approval on May 10, 2001 - the fastest FDA review for any cancer drug at the time, completed in eleven weeks.⁷ It didn't just treat a disease. It opened the era of targeted oncology, the move from blunt chemotherapy toward drugs aimed at a specific molecular fault.

That is the move worth studying. Not a joint venture, not an acquired consumer brand, but a step from one kind of science into a harder, more valuable one - and a step taken with an outside academic partner rather than a solo corporate triumph. The adjacency that compounds in pharmaceuticals is rarely a new product line you can buy. It's a new platform you can be early to. Novartis's most durable expansion was scientific, and the portfolio expansion it later unwound was, by comparison, just bookkeeping that took years to clean up.

But didn't diversification do its job before it was sold?

The honest objection is that this reading is too clean. The adjacencies weren't worthless. The consumer joint venture returned USD 13.0 billion in cash when Novartis sold its stake⁵ - hardly the proceeds of a failure. The merged breadth of 1996 may well have given the company the scale and financial cushion to fund the research that produced Gleevec in the first place. A conglomerate is not always a mistake; sometimes it is the scaffolding a focused business needs before it can stand alone. That is fair.

But notice what the cash exit actually proves. Selling a stake for USD 13.0 billion to 'focus on strategic priorities'⁶ is not the language of a company doubling down on adjacencies - it is a company telling you, in a press release, that the adjacency was worth more in someone else's hands than in its own. The scaffolding can be valuable and still be scaffolding. The test of an adjacency is not whether it ever made money. It is whether the parent is the best owner of it for the long run. Novartis kept answering that question 'no,' deal after deal, until only the medicines were left.

Novartis spent twenty-seven years discovering that the company it assembled in 1996 was not the company it wanted to be. The merger gave it everything - and the strategy was deciding, slowly and expensively, how much of everything to give back. The lesson isn't that diversification fails. It's that the headline gets it exactly backwards. The expansion that built lasting value wasn't a new aisle in the store; it was a single molecule that changed how a disease is fought. Everything else was a tenant. And one by one, Novartis showed each of them the door.